07:00 , Jun 20, 2016 |  BC Week In Review  |  Clinical News

ABP-700: Phase II started

The Medicines Co. began a single-blind, Dutch Phase II trial to evaluate IV ABP-700 in about 75 patients undergoing procedural sedation during elective colonoscopy. Patients will receive 50 ug/kg/min ABP-700 for 5 minutes followed by...
01:51 , Jan 21, 2016 |  BC Extra  |  Company News

Medicines Co. gains on takeout rumors

The Medicines Co. (NASDAQ:MDCO) gained $4.55 (14%) to $36.06 on Wednesday, giving it a market cap of $2.5 billion, after media reports said the company is exploring a sale. Spokesperson Robert Laverty declined to comment...
08:00 , Nov 9, 2015 |  BC Week In Review  |  Clinical News

ABP-700: Clinical trial data

The double-blind, placebo-controlled ANVN-01 clinical trial in 60 healthy volunteers showed that a single IV bolus injection of 0.03-1 mg/kg ABP-700 led to dose-dependent depth and duration of sedation as measured by both Modified Observer’s...
07:00 , Mar 23, 2015 |  BioCentury  |  Strategy

Show me the value

At a time when industry is struggling mightily with how to demonstrate the value of its products to payers and patients and translate that value into pricing, The Medicines Co. could provide some lessons. The...
02:24 , Feb 5, 2015 |  BC Extra  |  Company News

The Medicines Co. acquires Annovation

The Medicines Co. (NASDAQ:MDCO) exercised its option to acquire Annovation Biopharma Inc. (Cambridge, Mass.) for $28.4 million in cash up front. Annovation shareholders are eligible for up to $26.3 million in clinical and regulatory milestones,...